Insider Transactions in Q1 2021 at Ikena Oncology, Inc. (IKNA)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 30
2021
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
125,000
+12.5%
|
$2,000,000
$16.0 P/Share
|
|
Mar 30
2021
|
Jean Francois Formela |
BUY
Open market or private purchase
|
Indirect |
125,000
+12.5%
|
$2,000,000
$16.0 P/Share
|
|
Mar 30
2021
|
David P Bonita |
BUY
Conversion of derivative security
|
Indirect |
5,214,394
+50.0%
|
-
|
|
Mar 30
2021
|
David P Bonita |
BUY
Open market or private purchase
|
Indirect |
423,400
+21.9%
|
$6,774,400
$16.0 P/Share
|
|
Mar 30
2021
|
David P Bonita |
BUY
Conversion of derivative security
|
Indirect |
1,885,403
+50.0%
|
-
|
|
Mar 30
2021
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
4,750,361
+48.81%
|
-
|
|
Mar 30
2021
|
Otello Stampacchia |
BUY
Grant, award, or other acquisition
|
Indirect |
450,000
+16.67%
|
$7,200,000
$16.0 P/Share
|
|
Mar 30
2021
|
Otello Stampacchia |
BUY
Conversion of derivative security
|
Indirect |
1,799,123
+50.0%
|
-
|
|
Mar 30
2021
|
Jean Francois Formela |
BUY
Conversion of derivative security
|
Indirect |
4,750,361
+48.81%
|
-
|
|
Mar 30
2021
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
5,214,394
+50.0%
|
-
|
|
Mar 30
2021
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
423,400
+21.9%
|
$6,774,400
$16.0 P/Share
|
|
Mar 30
2021
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
1,885,403
+50.0%
|
-
|